Expression of TK gene detected with real-time PCR Sample Copy number (β-actin) Copy number (TK) Relative folds to β-actin 1 6.67E+07 2.78E+08 4.16792* 2 4.50E+07 1.13E+08 2.51111** 3 7.76E+07 2.17E+05 0.00279639 4 8.21E+07 Undetermined Undetermined 5 1.69E+08 1.39E+08 0.822485 Numbers 1, 2, 3, 4, 5 correspond to the numbers in Figure 3. 1: NPC 5-8F cells Belinostat supplier transfected with pGL3-basic- hTERTp-TK- EGFP- CMV; 2: MCF-7 transfected with pGL3-basic- hTERTp-TK- EGFP- CMV; 3: NPC 5-8F cells transfected with pGL3-basic- hTERTp-TK- EGFP; 4: NPC 5-8F cells transfected with pGL3-basic -TK-EGFP; 5: ECV cells transfected with pGL3-basic- hTERTp-TK- EGFP- CMV. Data are presented as mean ± standard deviation from these
experiments. *P < 0.0001 for sample 1 vs sample 3, sample 1 vs sample 5 and sample 2 vs sample 3. **P < 0.001 for sample 2 vs sample 5. 4. Reduced telomerase activity Semaxanib manufacturer by pGL3-basic-hTERTp-TK- EGFP-CMV/GCV Next we examined telomerase activity in PNC 5-8F cells transfected with the enhanced plasmid with or without GCV treatment. NPC 5-8F cells transfected with the enhanced plasmid were telomerase activity positive. However, the telomerase activity was decreased by 48 hours of GCV treatment. As control, ECV cells showed weak telomerase positive (Figure 3). Figure 3 GCV treatment down-regulates telomerase activity in 5-8F cells transfected with pGL3-basic-hTERTp-TK-EGFP-CMV. Shown are the silver stain visualized PCR products of telomerase
activities assay by PCR-based TRAP telomerase Mizoribine in vitro activity detection kit from NPC 5-8F cells transfected with enhanced plasmid pGL3-basic-hTERTp-TK-EGFP-CMV (lane 1), NPC 5-8F cells without transfection (lane 2), 5-8F cells transfected with pGL3-basic-hTERTp-TK-EGFP-CMV Edoxaban and treated with GCV (lane 3), and ECV cells itransfected with pGL3-basic-hTERTp-TK-EGFP-CMV and treated with GCV (lane 4). 5. Decreased survival rate of tumor cells transfected with the enhanced plasmid and treated with GCV Having confirmed that transfection of the enhanced plasmid increased the expression of TK, we further studied whether transfection of the enhanced plasmid could affect the effect of GCV on the survival rate of nasopharyngeal carcinoma NPC 5-8F cells and breast cancer MCF-7 cells by using MTT method. As shown in Tables 2 and 3, compared with non-transfected, untreated cells, transfection of control plasmid pGL3-basic-EGFP had no effect on survival rates of tumor cells 5-8F and MCF-7 with GCV treatment, and transfection of the enhanced plasmid pGL3-basic- hTERTp-TK-EGFP-CMV alone did not change the survival rates of tumor cells NPC 5-8F and MCF-7. However, after GCV treatment, survival rates of NPC 5-8F and MCF-7 cells transfected with the enhanced plasmid decreased to 0.370 ± 0.024 and 0.462 ± 0.